88512
document
Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine . The effect of zidovudine and didanosine on the cerebrospinal fluid ( CSF ) concentrations of neopterin was studied in 12 patients with human immunodeficiency virus type-1 ( HIV-1 ) infection 3-12 months after initiation of antiretroviral therapy . Ten treatment periods on zidovudine and 7 on didanosine were analysed . The CSF concentrations of neopterin decreased by 63 % ( from 29.6 to 12.9 nmol/l , p < 0.01 ) during zidovudine but increased by 15 % ( from 22.6 to 25.9 nmol/l , not significant during didanosine treatment . The CSF monocytic cell count decreased during zidovudine but increased during didanosine treatment . The results suggest that zidovudine but not didanosine reduces intrathecal immunoactivation during HIV-1 infection .
88513
Intervention_Pharmacological
zidovudine
88514
Intervention_Pharmacological
didanosine
88515
Intervention_Pharmacological
zidovudine
88516
Intervention_Pharmacological
didanosine
88517
Intervention_Pharmacological
antiretroviral therapy
88518
Intervention_Pharmacological
zidovudine
88519
Intervention_Pharmacological
didanosine
88520
Intervention_Pharmacological
zidovudine
88521
Intervention_Pharmacological
didanosine
88522
Intervention_Pharmacological
zidovudine
88523
Intervention_Pharmacological
didanosine
88524
Intervention_Pharmacological
zidovudine
88525
Intervention_Pharmacological
didanosine
88526
Outcome_Physical
Intrathecal immunoactivation
88527
Outcome_Physical
CSF concentrations of neopterin
88528
Outcome_Physical
CSF monocytic cell count
88529
Outcome_Physical
intrathecal immunoactivation during HIV-1 infection
88530
Participant_Condition
patients with HIV-1 infection
88531
Participant_Sample-size
12
88532
Participant_Condition
human immunodeficiency virus type-1
88533
Participant_Condition
HIV-1
88534
Participant_Condition
HIV-1